Spinal Cord Stimulator Device Market Scope And Analysis

  • Report Code : TIPRE00016810
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Spinal Cord Stimulator Device Market Analysis, Size, and Growth (2021-2022)

Buy Now


Spinal Cord Stimulator Device Market Report Scope

Report Attribute Details
Market size in 2022 US$ 2,779.91 Million
Market Size by 2030 US$ 4,967.52 Million
Global CAGR (2022 - 2030) 7.5%
Historical Data 2020-2022
Forecast period 2022-2030
Segments Covered By Product Type
  • Rechargeable and Non-Rechargeable
By Application
  • Failed Back Syndrome
  • Complex Regional Pain Syndrome
  • Degenerative Disk Disease
By End User
  • Hospitals
  • Ambulatory Surgery Centers
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Boston Scientific Corp
  • Nevro Corp
  • Abbott Laboratories
  • Cirtec Medical Corp
  • Medtronic Plc
  • Biotronik SE Co KG
  • Curonix LLC
  • Nalu Medical Inc
  • Synapse Biomedical Inc
  • Industry Developments and Future Opportunities: 

    Key initiatives by major players operating in the Spinal Cord Stimulator Device Market are listed below:

    1. In August 2022, Abbott Laboratories received approval from the US FDA for its Proclaim Plus SCS system to treat chronic pain. The BurstDR stimulation technology enables the device to deliver superior pain relief. It offers FlexBurst360 therapy that offers pain coverage across the trunk and limbs; the device can be programmed per the patient's evolving therapeutic needs.
    2. In December 2022, the Eterna spinal cord stimulation (SCS) system from Abbott Laboratories will be available to treat chronic pain. Abbott's low-dose BurstDR stimulation, a patented low-dose SCS waveform technology with the greatest clinical evidence, has been approved by the FDA. Additionally, it has been demonstrated that the technique aids in 23% more pain reduction than the results produced by conventional waveform technology-based methods.

    Competitive Landscape and Key Companies:

    A few of the prominent players operating in the spinal cord stimulator device market are Boston Scientific Corp; Nevro Corp; Abbott Laboratories; Cirtec Medical Corp; Medtronic Plc; Biotronik SE & Co KG; Curonix LLC; Nalu Medical, Inc.; and Synapse Biomedical Inc. These companies focus on new product launches and geographic expansions to meet global consumer demand and increase their product range in specialty portfolios. Their global presence allows them to serve a large base of customers, subsequently facilitating market expansion.